fig1
Figure 1. Biomarkers to evaluate the efficacy of immunotherapy. PD-L1 IHC staining and TMB validated by clinical guidelines, HPV status and characteristics of TIL are under study. PD-L1: Programmed death-ligand 1; IHC: immunohistochemistry; TMB: tumor mutation burden; HPV: human papillomavirus; TIL: tumor immune infiltration; R/M HNSCC: recurrent/metastatic head and neck squamous cell carcinoma; CPS: combined positive score; 5-FU: 5-fluorouracil.
